Search

everythinglearnresearchcommunity

for

Search:↓

The European Society of Endocrinology advises individualized long-term management for PCOS, focusing on lifestyle changes, accurate diagnosis, and treatments for associated health risks and symptoms.

Dehydroepiandrosterone (DHEA) is a prohormone important for producing sex steroids and has potential health benefits.

The document concludes that hormonal biomarkers are key for diagnosing hyperandrogenemia in women and hypogonadism in men.

Stress worsens symptoms and body changes in women with PCOS, especially during COVID-19.

A comprehensive, personalized approach is needed for treating female pattern hair loss and obesity, involving multiple medical disciplines and lifestyle changes.

Excess androgens may cause PCOS, not just be a symptom.

High levels of male hormones, insulin resistance, and obesity are closely linked and worsen polycystic ovary syndrome, but more research is needed to improve treatments.

The conclusion is that PCOS is caused by ovarian sensitivity to hormones and disrupted hormone control, possibly due to ovarian factors, and more research is needed.

Many infertile women with PCOS in Central Vietnam have metabolic or insulin resistance syndrome, with obesity and older age increasing the risk.

Obesity is linked to higher metabolic syndrome and LH/FSH ratios, but no significant differences exist among PCOS phenotypes.

There is no cure for myotonic dystrophy type 1, so treatment focuses on managing symptoms and complications.

The document concludes that PCOS is a complex disorder caused by both genetic and environmental factors, affecting women's health in various ways, and requires personalized treatment.

Women with PCOS should be screened for heart disease risk and manage their health to prevent it.

The document concludes that insulin resistance is key in PCOS development and early treatment is crucial to prevent complications.

Obesity increases the risk of developing polycystic ovary syndrome, and weight loss can improve the condition.

Women with PCOS may take longer to get pregnant but can have a normal family size, and should manage their overall health to reduce long-term health risks.

Blocking the enzyme 11β-HSD1 might help treat obesity and metabolic issues.

Oxidative stress is a key factor in the development of Polycystic Ovary Syndrome, and weight management can improve symptoms.

Metformin combined with lifestyle changes improves insulin resistance and reduces testosterone levels in women with PCOS more than lifestyle changes alone.

Targeting glucocorticoid action might help treat type-2 diabetes, but human trials are needed.

Testosterone replacement may improve sexual desire and bone health in women with low androgen levels, but more research is needed on its long-term safety.

Polycystic Ovary Syndrome is common but often undiagnosed, and early treatment is important to prevent health problems.

The conclusion is that genetic changes in the glucocorticoid receptor can lead to conditions affecting stress response, immunity, and metabolism, requiring personalized treatment.

Girls with PCOS during adolescence have a higher risk of developing type 2 diabetes, and early treatment can help manage this risk.

Early diagnosis and treatment of PCOS is crucial to reduce emotional distress and health risks.

Some hair loss and prostate drugs might increase the risk of diabetes and heart disease.

Overweight women with PCOS have higher levels of certain hormones that could indicate a higher risk of heart and metabolic problems.

Low-dose anti-androgen drugs and certain drug combinations are effective for hirsutism, and insulin sensitizers show promise, especially for those with polycystic ovarian syndrome.

Women with PCOS have a higher risk of heart disease due to factors like insulin resistance and obesity.

Testosterone replacement may help postmenopausal women with sexual function and bone density, but suitable treatments are limited.